Statements (86)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
2
|
| gptkbp:bfsParent |
gptkb:physicist
|
| gptkbp:acquired |
various companies
|
| gptkbp:acquisition |
gptkb:Alcon_(2011)
gptkb:Sandoz_(2003) Advanced Accelerator Applications (2018) Aileron Therapeutics (2021) Apexigen (2021) Astra Zeneca's diabetes business (2013) Astra Zeneca's heart failure business (2014) Astra Zeneca's oncology business (2015) Astra Zeneca's respiratory business (2016) Ave Xis (2018) Biosimilars business from Amgen (2019) Chugai Pharmaceutical (2002) Endocyte (2018) Genoptix (2011) Hexal AG (2005) Medi Beacon (2021) Medi Wound (2021) Molecular Partners (2021) The Medicines Company (2020) Ziarco Pharma (2016) Zymeworks (2021) Acquired Alcon in 2011 |
| gptkbp:ceo |
gptkb:Vas_Narasimhan
Vas Narasimhan since 2018 |
| gptkbp:clinical_trial |
Conducts numerous clinical trials globally
|
| gptkbp:employees |
Over 100,000
approximately 110,000 |
| gptkbp:focus |
Research and development of pharmaceuticals
|
| gptkbp:founded |
gptkb:1996
|
| gptkbp:global_presence |
over 140 countries
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novartis
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:invention |
Holds thousands of patents worldwide
|
| gptkbp:is_divided_into |
gptkb:Alcon
gptkb:Sandoz Pharmaceuticals |
| gptkbp:key_people |
gptkb:Vas_Narasimhan
|
| gptkbp:operates_in |
gptkb:Company
|
| gptkbp:parent_company |
gptkb:none
|
| gptkbp:partnership |
GSK (Glaxo Smith Kline) for vaccines
Microsoft for AI in healthcare Google (2020) Microsoft (2020) Collaborations with various biotech companies |
| gptkbp:philanthropy |
gptkb:Novartis_Foundation
|
| gptkbp:products |
gptkb:Aimovig
gptkb:Cosentyx gptkb:Entresto gptkb:Gleevec gptkb:Jakavi gptkb:Kymriah gptkb:Tafinlar gptkb:Zolgensma generic drugs vaccines Innovative medicines innovative medicines |
| gptkbp:research_areas |
gptkb:healthcare_organization
gptkb:sneaker Immunology Neuroscience Cardiovascular |
| gptkbp:research_focus |
oncology
neuroscience cardiovascular diseases immunology ophthalmology cardiovascular |
| gptkbp:revenue |
$48.5 billion (2020)
|
| gptkbp:social_responsibility |
gptkb:Sustainability_initiatives
Health education programs Access to medicines Research funding for neglected diseases |
| gptkbp:stock_exchange |
gptkb:NYSE
|
| gptkbp:subsidiary |
gptkb:Alcon
gptkb:Sandoz |
| gptkbp:sustainability |
Commitment to environmental sustainability
|
| gptkbp:symbol |
NVS
|
| gptkbp:traded_on |
gptkb:NYSE
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
novartis.com
|